Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Cash from Financing Activities of $274.5 million for Q3 2025, up 92640.88% year-over-year from N/an in Q3 2024, and up 48229.75% quarter-over-quarter from $568000.0 in Q2 2025.
Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $274.5 million for Q3 2025.
- In Q3 2025, Cash from Financing Activities rose 92640.88% year-over-year to $274.5 million; the TTM figure through Sep 2025 stood at $314.9 million (up 49.19% YoY), while the FY2024 annual figure was $255.6 million, up 91.37% from the prior year.
- Cash from Financing Activities for Q3 2025 stood at $274.5 million, up from $568000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $274.5 million in Q3 2025, with the low at -$4.9 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is $418000.0 (2021), against an average of $56.7 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 99.94% in 2022, then jumped 92640.88% in 2025.
- Dianthus Therapeutics' Cash from Financing Activities stood at $124000.0 in 2021, then soared by 77825.0% to $96.6 million in 2022, then slumped by 105.03% to -$4.9 million in 2023, then surged by 915.54% to $39.7 million in 2024, then soared by 591.89% to $274.5 million in 2025.
- Business Quant data shows DNTH's Cash from Financing Activities at $274.5 million in Q3 2025, $568000.0 in Q2 2025, and $161000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 274.51 Mn |
| Sep 30, 2025 | 274.51 Mn |
| Jun 30, 2025 | 568,000.00 |
| Jun 30, 2025 | 568,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 39.68 Mn |
| Dec 31, 2024 | 39.68 Mn |
| Sep 30, 2024 | 296,000.00 |
| Sep 30, 2024 | 296,000.00 |
| Jun 30, 2024 | -2.20 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | 217.85 Mn |
| Mar 31, 2024 | 217.85 Mn |
| Dec 31, 2023 | -4.87 Mn |
| Dec 31, 2023 | -4.87 Mn |
| Sep 30, 2023 | 138.44 Mn |
| Sep 30, 2023 | 138.44 Mn |
| Sep 30, 2022 | 96.63 Mn |
| Sep 30, 2022 | 96.63 Mn |